All In Biotech

Drug Trial Radar · NCT07795346

A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

A Randomized, Controlled, Open-label, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ATG-022 Compared With Investigator's Choice of Treatment in Subjects With Claudin18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Sep 17, 2026

Primary completion

Dec 31, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Antengene Biologics LimitedIndustry
Sponsor type
Industry
First posted
Aug 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label, multicenter Phase III study to evaluate the efficacy and safety of ATG-022 compared with Investigator's Choice in participants with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Conditions

  • Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

  • ATG-022Drug

    1.8 mg/kg,D1, Q3W,every 21 days as one cycle

  • Docetaxel or IrinotecanDrug

    Docetaxel: 75-100 mg/m², D1, Q3W, every 21 days as one cycle Irinotecan: 125 mg/m², D1, D8, Q3W, every 21 days as one cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival(PFS )Time frame: From randomization to first PD or death. Tumour assessments at baseline, q6w (±1w) during treatment, q12w (±1w) after 12m, q24w (±1w) after 24m, until PD/death/study end (~228 OS events, ~1yr after LPI).
  2. Overall Survival(OS)Time frame: From randomization to death. Survival follow-up q3m (±14d) until death/study termination (~228 OS events).

Locations

131 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Tenth People's Hospital

    Shanghai, China · Not yet recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, China · Not yet recruiting

  • The First Hospital of Shanxi Medical University

    Taiyuan, China · Not yet recruiting

  • Taizhou People's Hospital

    Taizhou, China · Not yet recruiting

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China · Not yet recruiting

  • Xuzhou Central Hospital

    Xuzhou, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China · Not yet recruiting

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China · Not yet recruiting

  • Fuyang Hospital of Anhui Medical University (The Fifth Affiliated Hospital of Anhui Medical University)

    Fuyang, Anhui, China · Not yet recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)

    Hefei, Anhui, China · Not yet recruiting

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing GoBroad Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Peking University First Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqi, Chongqing Municipality, China · Not yet recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Fujian Provincial Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Not yet recruiting

  • Gansu Cancer Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Gansu Cancer Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Gansu Provincial People's Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Gansu Wuwei Tumour Hospital

    Wuwei, Gansu, China · Not yet recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine

    Guangzhou, Guangdong, China · Not yet recruiting

  • The First Affiliated Hospital,Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The Third Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Cancer Hospital of Shantou University Medical College

    Shantou, Guangdong, China · Not yet recruiting

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Not yet recruiting

  • Hainan Cancer Hospital

    Haikou, Hainan, China · Not yet recruiting

  • The First Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China · Not yet recruiting

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China · Not yet recruiting

  • Affiliated Hospital of Hebei University

    Baoding, Hebei, China · Not yet recruiting

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China · Not yet recruiting

  • Cangzhou People's Hospital

    Cangzhou, Hebei, China · Not yet recruiting

  • Handan Central Hospital

    Handan, Hebei, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

Showing 40 of 131 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.